Positive results for neurotrophin-3 inhibitor in osteoarthritis
Phase II trial results for Levicept’s LEVI-04, a novel and first in class neurotrophin-3 (NT-3) inhibitor, have shown that the drug was highly effective and well tolerated. The study enrolled more than 510 participants with pain and disability due to osteoarthritis of the knee. It was… Read More